People suffering from psoriasis may soon benefit from a drug that offers greater efficacy than the current standard of care, revealed phase II human trial. Nine-month treatment with the new drug was found to clear skin in more than 80% of psoriasis-affected patients. The study is published in the New England Journal of Medicine.
Psoriasis is a chronic skin condition that causes itchy, dry and red skin. It affects nearly 3% of the world's population, and also increases a patient's risk for depression, heart disease and diabetes, among other conditions.
Researchers compared the new drug guselkumab to adalimumab, the most common medication currently used to treat psoriasis. In the trial, 293 adult patients with moderate-to-severe psoriasis (defined as covering 10% or more of the body) were randomly assigned to receive varying doses of one of the two drugs or a placebo over 52 weeks. At weeks 16 and 40, efficacy of both the drugs was measured on a scale of zero to five. A significantly higher number of patients in the guselkumab group had a score of zero (cleared psoriasis) or one (minimal psoriasis) in both the short and long term periods compared to the adalimumab and placebo groups. At week 40, for example, 81% of patients taking a 200-mg dose of guselkumab had a score of zero or one, compared to 49% of patients taking adalimumab.
An ongoing phase III trial is continuing to test the safety and efficacy of guselkumab as a potential psoriasis treatment.
Subscribe to PharmaTutor News Alerts by Email >>
